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A radiogenomics application for prognostic
profiling of endometrial cancer
Erling A. Hoivik 1,2,3,4,5✉, Erlend Hodneland3,4,5, Julie A. Dybvik 3,4, Kari S. Wagner-Larsen3,4,
Kristine E. Fasmer3,4, Hege F. Berg 1,2, Mari K. Halle1,2, Ingfrid S. Haldorsen 3,4,6✉ &
Camilla Krakstad 1,2,6✉
Prognostication is critical for accurate diagnosis and tailored treatment in endometrial cancer
(EC). We employed radiogenomics to integrate preoperative magnetic resonance imaging
(MRI, n= 487 patients) with histologic-, transcriptomic- and molecular biomarkers (n= 550
patients) aiming to identify aggressive tumor features in a study including 866 EC patients.
Whole-volume tumor radiomic profiling from manually (radiologists) segmented tumors
(n= 138 patients) yielded clusters identifying patients with high-risk histological features and
poor survival. Radiomic profiling by a fully automated machine learning (ML)-based tumor
segmentation algorithm (n= 336 patients) reproduced the same radiomic prognostic groups.
From these radiomic risk-groups, an 11-gene high-risk signature was defined, and its prog-
nostic role was reproduced in orthologous validation cohorts (n= 554 patients) and aligned
with The Cancer Genome Atlas (TCGA) molecular class with poor survival (copy-number-
high/p53-altered). We conclude that MRI-based integrated radiogenomics profiling provides
refined tumor characterization that may aid in prognostication and guide future treatment
strategies in EC.
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Endometrial cancer (EC) is the most prevalent cancer of thefemale reproductive tract in countries ranked within thehighest tier of the human developmental index, with obesity
being a strong predisposing factor1,2. While most EC patients
have a favorable prognosis, identification of high-risk EC disease
is essential to determine optimal surgical treatment and potential
adjuvant therapies3,4. Preoperative risk stratification is based
on endocervical curettage (biopsy) or endometrial pipelle
sample often combined with preoperative imaging, such as pelvic
magnetic resonance imaging (MRI) for local staging3,5,6. The
increased use of advanced preoperative imaging and the intro-
duction of novel machine learning techniques have opened for in-
depth analyses of tumor characteristics relevant for diagnosis and
prognostication. Radiomics is an emerging technique allowing
tumor profiling by extracting quantitative information from
medical images using mathematical descriptors and has been
shown to predict clinical- and molecular tumor characteristics,
survival, and response to treatment across various cancers7,8.
Radiogenomics combines radiomics with genomic data to non-
invasively determine underlying molecular characteristics7–11.
Radiogenomics-based models reportedly predict genetic variants,
i.e., mutations, microsatellite instability (MSI), gene expression,
and tumor heterogeneity in non-small cell lung cancer and breast
cancer, making this approach highly promising for developing
personalized medicine11–14.
An increasing number of radiomics studies have linked
radiomic profiling to prognosis in EC. Studies based on com-
puted tomography (CT), MRI, and positron emission tomo-
graphy (PET)-CT from single slice tumor segmentations15–21
and whole-volume tumor segmentations14,22–25 have identified
radiomic signatures associated with high-risk features and
poor prognosis15–18,20,21. Radiomic models predicting lymph
node metastasis in EC have also been published22–25. Recently,
whole-volume tumor radiomics from contrast-enhanced CT
(CE-CT) was shown to predict high mutational burden in ECs,
including The Cancer Genome Atlas (TCGA)-equivalent MSI
tumors14. Similarly, a single-slice MRI radiomic prognostic
index vector was recently linked to a specific gene expression
signature that predicted poor outcome in EC18. Furthermore,
deep-learning applications using MRI in EC have been used
to derive valid automated tumor segmentations26 and report-
edly provide promising models for automatic determination of
myometrial depth27,28.
The aim of this study was to develop a novel radiogenomics
approach using noninvasive, preoperative whole-volume tumor
MRI for expedited radiomic based individual risk assessment and
develop a corresponding prognostic gene expression signature in
EC patients. Furthermore, we aimed to assess whether ML-based
automated whole-volume tumor segmentations yield similar
radiomic profiles that may be linked to the same gene expression
signature.
Results
Unsupervised clustering of radiomic profiles identifies patients
with high-risk clinico-pathological characteristics and poor
outcome. A total of 866 EC patients were included in this study, of
which 487 patients had available preoperative whole-volume tumor
MRI and 554 patients had mRNA expression profiles and/or
molecular markers. An outline of the approach to integrate radio-
mic, transcriptomic, molecular makers, and clinico-pathological
data is displayed in Fig. 1. Fifty-three radiomic features were
extracted from manually segmented primary tumors depicted at
MRI in 138 EC patients. MRI sequences (VIBE+C, ADC, b1000)
and the corresponding manual tumor segmentation mask used for
radiomic tumor profiling is shown for one representative patient in
Fig. 2a. A robust linear regression demonstrated a weak positive
correlation between tumor volume and z-normalized “normsurf-
volratio” (MATLAB, “robustfit”, n= 336, slope= 0.0090ml−1,
p= 0.0013). A similar curve fit for tumors with V > 1ml yielded no
significant correlation between z-normalized “normsurfvolratio”
and tumor volume (MATLAB, “robustfit”, n= 288, slope=
0.0043ml−1, p= 0.13), hence suggesting independency of tumor
volume in larger tumors.
Unsupervised clustering of the radiomic features identified two
distinct patient clusters; cluster 1 (n= 70) and cluster 2 (n= 68).
Cluster 2 was characterized by higher values for “clusterindex”,
“clustersize”, “homogeneity”, “energy”, “correlation”, and “LRE”
and lower values for the radiomic features “contrast” and “SRE”,
compared to cluster 1. Cluster 2 was subsequently re-clustered
into subclusters 2a (n= 44) and 2b (n= 24) using the same
unsupervised clustering algorithm; 2b had higher values for
“LGRE” and “clustersize”, and lower values for “HGRE”
compared to cluster 2a (Fig. 2b). Patients in clusters 2a/b more
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Fig. 1 Radiogenomics approach in the current study of 866 endometrial
cancer patients. Overview of the analytical approach integrating radiomics
(red), genomics (blue), and clinical/pathological data (green). Preoperative
MRI from 487 endometrial cancer patients were used for primary tumor
segmentation using two approaches; (i) manual segmentation by
radiologists (training cohort, 138 patients) and (ii) automated segmentation
(using machine learning [ML] validation cohort, 349 patients, of which 13
patients were excluded due to failed automated tumor detection).
Unsupervised clustering of extracted radiomic features in the manually
segmented cohort (n= 138) yielded distinct radiomic clusters tested for
differences in survival and clinico-pathological characteristics. Similarly,
upon feature extraction, patients assigned to clusters by the automated
segmentation approach (n= 336) were tested for survival differences.
Resected tumors were profiled by transcriptome expression and analyzed
for molecular markers. Transcriptome profiles were obtained by L1000 and
Agilent expression array data (554 patients, 98 overlappings). For a subset
of patients (hexagon, n= 51), MRI, expression profiles, and TCGA
molecular classes were available, enabling the generation of a gene
signature. The gene signature was validated in all transcriptome datasets,
including the external TCGA RNA sequencing expression dataset (n= 298)
and evaluated in survival analysis.
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often presented high-risk clinico-pathological features including
deep myometrial infiltration (>50%; p= 0.001), lymph node
metastases (p= 0.020), high-grade histology (p= 0.001), non-
endometrioid subtype (p= 0.014), and advanced FIGO stages
(p= 0.006) (Fig. 2b, bottom panel; Table 1). Cluster 2b tumors
were of higher grade (p= 0.050) and were more likely to be
of non-endometrioid type (p= 0.050) compared to tumors of
cluster 2a (Supplementary Table S1). Inter-centroid distance for
all radiomic features indicated that no single radiomic feature was
able to discriminate between the three clusters and that the
interdependency across features was pronounced (Fig. 2c). When
accounting for centroid inter-distance, two volume-related
features (“normsurfvolratio” and “vol”) were ranked as the most
important features describing the three clusters.
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Patients in cluster 2 exhibited significantly reduced disease-
specific survival (p < 0.001, Fig. 2d). Furthermore, patients in
cluster 1, 2a, and 2b had significantly different disease-specific-
and recurrence-free survival (overall p < 0.001; Fig. 2e, f) with the
best outcome for patients in cluster 1, the intermediate outcome
for patients in cluster 2a, and poorest outcome for patients in
cluster 2b.
After dilation and erosion of the segmentation masks, only
14% (20/138) or 8% (11/138) of the cases changed clusters upon
dilation and erosion, respectively. Furthermore, the finding that
patients in the three clusters had significantly different survival
was reproduced (p ≤ 0.001 for all; Supplementary Fig. S1).
An 11-gene radiogenomic signature predicts aggressive EC
phenotypes and poor survival. We performed a differential gene
expression analysis (significance of microarray analysis; SAM) of
the radiomic clusters (comparing clusters 1 to 2b, or all three
clusters) from patients with overlapping MRI and transcriptome
data (n= 51). Eleven genes overlapped between the two analyses
and were selected to compute a robust signature of differentially
expressed genes for the radiomic clusters. The gene signature
included three upregulated genes; HSPA5, GATA3, and
HSP90AA1, and eight downregulated genes; SCGB2A1, GSTK1,
MMP7, GDF15, ANXA1, SAT1, CNDP2, and PBX1, related to the
most aggressive clusters (Table 2). Patients with tumors of high
signature score (cutoff above mean signature score) more often
exhibited non-endometrioid histologic type (p= 0.019) and
tended to be high-grade tumors (p= 0.09) with advanced FIGO
stage (p= 0.23). High signature score patients also had bio-
marker patterns (Fig. 3a, middle panel) associated with aggres-
sive disease described by loss/low levels of the hormone receptors
ER (p= 0.037), PR (p= 0.005), and AR (p= 0.013) (Supple-
mentary Table S2). In addition, substitute TCGA-markers
(Fig. 3a) indicated that patients with high signature scores
were more often classified as TCGA-copy-number-high (p53
abnormal expression; 87% [7/8 cases]) known to indicate a poor
prognosis, and clustered to the radiogenomics cluster 2a/b.
Patients with low signature scores were more often of the TCGA
equivalent POLE class tumors (3/3 cases) indicating favorable
prognosis, while the “MSI”- and “CNL”-like classes were more
evenly distributed for the high/low signature score groups. We
compared the dichotomous high/low gene expression signature
levels with the radiomics clusters (cluster 1 vs. 2a/b) among the
51 samples with overlapping data and found that a significantly
higher proportion of patients within cluster 1 had a low signature
score (84%; 16/19), compared to that of patients within cluster 2
(34%; 11/32) (p= 0.001). The high signature score predicted
poor survival in patients with overlapping radiogenomics data
(n= 51; Fig. 3b; p= 0.0006) and the poor prognostic impact of
the high signature score was reproduced in the EC cohort with
full L1000 gene expression data (n= 392) (Table 3, all clinico-
pathological variables highly significant; Fig. 3c, p < 0.0001).
Also, in the subgroup of patients having low-risk histology
(endometrioid, grade 1–2) based on preoperative cur-
ettage(pipelle)/endometrial biopsy, the 11-gene signature had a
prognostic impact with high signature score predicting aggres-
sive clinico-pathological features and poor survival (n= 296,
Supplementary Table S3 and Fig. 3d; p= 0.00012). The asso-
ciation between high signature score and high-risk disease/poor
outcome, was also reproduced in the Agilent expression dataset
(n= 256 patients; Fig. 3e; p < 0.0001; Supplementary Table S4)
and in an external EC RNA sequencing dataset from TCGA
(n= 298; Supplementary Fig. S2; p= 0.0019). In the latter, a
higher proportion of TCGA-copy-number-high (Serous-like)
class tumors was also observed in patients with high signature
Fig. 2 Unsupervised clustering of radiomic (3D) tumor features in 138 EC patients yields distinct clusters displaying different prevalence of high-risk
features. a Preoperative pelvic MRI with manual tumor segmentation of the primary tumor (red arrows) of a patient with endometrioid type, histologic
grade 1, and FIGO stage IA. The following MRI sequences were used for radiomic profiling of the manual segmentation-cohort; contrast-enhanced
volumetric interpolated breath-hold examination (VIBE+C), apparent diffusion coefficient (ADC) map and diffusion-weighted sequence with b-value of
1000 (b1000) using the segmentation mask as that for VIBE+ C. b Unsupervised clustering reveals three radiomic clusters with differences in clinico-
pathological variables, reflecting differences in their risk-profiles. Patients in cluster 2a (n= 44) and cluster 2b (n= 24) more often had high-risk clinico-
pathological features compared to patients in cluster 1 (n= 70). c Representing feature importance of the 53 derived radiomic features in terms of pairwise
cluster centroid inter-distance (solid lines with open dots) and the aggregated value (open dots, “All clusters”; scaled for visualization). A large pairwise
inter-distance indicates discriminating properties of large importance between clusters for a given texture feature. d–f Kaplan–Meier survival curves
depicting significantly reduced disease-specific survival among radiomic clusters 1 and 2a/b combined (d), all three clusters (e), or by recurrence (f). The
number of events in brackets. Histological types; EEC endometrioid, CS carcinosarcoma, S serous, CC clear cell, U undifferentiated.
Table 1 Clinico-pathological variables in relation to the
radiomic clusters based on the manually segmented tumors
(n= 138).
Variable Description Radiomic clusters, n (%) p valuea
Cluster 1
(n= 70)
Cluster
2a/b
(n= 68)
Age <66 38 (57.6) 28 (42.4) 0.130
≥66 32 (44.4) 40 (55.6)
Histologic type Endometrioid 63 (56.3) 49 (43.8) 0.014
Non-
endometrioid
7 (28.0) 18 (72.0)
Histologic
gradeb
Grade 1–2 55 (63.2) 32 (36.8) 0.001
Grade 3 5 (22.7) 17 (77.3)
FIGO stage I–II 66 (55.9) 52 (44.1) 0.006
III–IV 4 (21.1) 15 (78.9)
Myometrial
infiltration
<50% 56 (75.7) 18 (24.3) <0.001
≥50% 14 (22.2) 49 (77.8)
Lymph node
metastasis
No 40 (48.8) 42 (51.2) 0.020
Yes 2 (14.3) 12 (85.7)
Ploidy Diploid 24 (43.6) 31 (56.4) 0.424
Aneuploidy 6 (31.6) 13 (68.4)
ER protein
expressionc
High
expression
27 (52.9) 24 (47.1) 0.059
Low
expression
8 (29.6) 19 (70.4)
PR protein
expressionc
Positive 31 (52.5) 28 (47.5) 0.064
Negative 5 (26.3) 14 (73.7)
AR protein
expressionc
Positive 16 (51.6) 15 (48.4) 0.451
Negative 12 (41.4) 17 (58.6)
Missing data (numbers): Histologic type (1), Histologic grade (3), FIGO stage (1), Myometrial
infiltration (1).
Not assessed (numbers): Lymph node metastasis (42), Ploidy (64), ER (60), PR (60), and
AR (78).
Including one inoperable patient.
a Calculated with Chi-Square test or Fischer’s exact test, as appropriate.
b Endometrioid type only.
c Protein levels by immunohistochemistry (IHC).
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score (49%; 48/97) compared to that of patients with low sig-
nature scores (9%; 12/135; p < 0.0001).
ML-based clustering of patients in the validation cohort con-
firms the link to poor prognosis. When applying the fully auto-
mated machine learning algorithm, the tumor was not detected in
3% (13/349) of the patients and these cases were excluded
in subsequent radiomic analyses. For the remaining 336 patients, a
53-feature radiomic cluster analysis was applied using the same
algorithm as that for the manually segmented datasets. This yielded
clusters comprising 188, 84, and 64 patients in clusters 1, −2a, and
−2b, respectively. MRI (VIBE+C, ADC, b1000) with the auto-
mated ML-derived tumor segmentation in one representative
patient are shown in Fig. 4a. The heatmap of radiomic features for
the different clusters (Fig. 4b) showed highly similar discriminating
features between the ML clusters to that observed for the manually
segmented tumors (Fig. 2b). In agreement with results from the
manually segmented dataset, patients in clusters 2a/b more often
presented with high-risk clinico-pathological features (Fig. 4b
and Supplementary Table S5) and had significantly reduced
disease-specific (p < 0.0001, Fig. 4c, d) and recurrence-free survival
(p= 0.003, Fig. 4e). Cluster 2b tumors had higher FIGO
stages (p= 0.003) and were associated with lymph node metastases
(p= 0.004), compared to tumors of cluster 2a (Supplementary
Table S6).
When comparing the gene expression signature levels across
radiomics clusters (clusters 1 and clusters 2a/b) in 98 cases
overlapping with the ML-cohort, low signature score tended to be
more frequent (74%; 37/50) in patients within cluster 1 compared
to that in patients within cluster 2 (56%; 27/48) (p= 0.089).
Discussion
Radiogenomics, linking imaging-, and genomic tumor data, has
demonstrated encouraging results in predicting tumor char-
acteristics and survival across many cancer types (reviewed in
ref. 8). This study, encompassing 866 patients, allowed an
unprecedented integrative radiogenomics characterization of
EC. Our results show that MRI radiomic tumor profiling iden-
tifies distinct radiomic clusters that differentiate between patient
groups having significantly different clinico-pathological char-
acteristics and prognosis. Importantly, these radiomic signatures
are associated with specific transcriptional programs, suggesting
that noninvasive radiomic profiling may aid in assessing patient
risk and characterize transcriptional profiles relevant for tumor
biology. The identification and validation of distinct radiomic
phenotypes emphasize the promising role of radiomic pheno-
typing as support for developing risk-stratified targeted treat-
ment strategies in EC.
We used two approaches for whole-volume tumor segmenta-
tions; manual tumor segmentation (n= 138) performed by expert
radiologists, and automated deep-learning-based 3D tumor seg-
mentation (n= 349). Interestingly, similar radiomic clusters
derived from the manual tumor segmentations were reproduced
in the radiomic clusters from automated tumor segmentations,
and both datasets identified differential transcriptomic signatures,
specific clinico-pathological patient characteristics, and different
prognosis for the radiomic clusters. For the automated approach,
we deployed a convolutional neural network (CNN) deep-
learning algorithm allowing expedited whole-volume tumor seg-
mentations, which has been shown to yield tumor segmentations
with accuracies comparable to that between radiologists26. This
finding is supported by the present study suggesting that the
approach for automated whole-volume radiomic profiling seems
to be valid enough to allow clinical phenotyping and point to
likely transcriptional signatures.
The radiomic patient clusters were solely based on radiomic
features from the EC tumors without prior feature selection9.
Radiomic studies report a variable number of features included in
their models, presumably related to the imaging modality used,
available sequences, and the complexity of the applied radiomic
extraction algorithms7. We used an approach deriving only 53
features, without subsequent dimensionality reduction. This dif-
fers from most studies reporting a multitude of image features
with subsequent selection of top features to optimize their
models9,10. When investigating the interrelationship amongst the
53 features in this study, no single feature was alone able to
differentiate between the three clusters (Fig. 2). However, volume-
related vectors yielded the longest centroid distance for distin-
guishing between radiomic cluster 1 and 2b (exhibiting favorable
and dismal prognosis, respectively), suggesting a tendency of
tumor size to affect clustering. Previously, large tumor size on
MRI has been shown to predict deep myometrial invasion, lymph
node metastases, high histological grade, advanced FIGO stage,
and poor survival in EC, descriptive of aggressive disease15,22. We
found the radiomic feature “normsurfvolratio” to be independent
of tumor volume for tumors with volume >1 ml (p= 0.14). Most
importantly, this parameter was ranked as the single most
important radiomic feature for separating the clusters (Fig. 2d),
suggesting that an irregularly shaped tumor is an important
predictor of high-risk disease.
We report similar prognostic discrimination by clusters based
on dilated and eroded segmentation masks to that based on
baseline segmentation masks. Thus, it seems reasonable to con-
clude that the proposed workflow for feature extraction and
clustering is relatively resistant against noise and minor changes
of the segmentation masks.
Table 2 List of 11 genes in signature.
Gene name Signature directionb Entrez gene accession id Gene description (HGNC Symbola)
HSPA5 Up ENSG00000044574 Heat shock protein family A (Hsp70) member 5
GATA3 Up ENSG00000107485 GATA binding protein 3
HSP90AA1 Up ENSG00000080824 Heat shock protein 90 alpha family class A member 1
SCGB2A1 Down ENSG00000124939 Secretoglobin family 2A member 1
GSTK1 Down ENSG00000197448 Glutathione S-transferase kappa 1
MMP7 Down ENSG00000137673 Matrix metallopeptidase 7
GDF15 Down ENSG00000130513 Growth differentiation factor 15
ANXA1 Down ENSG00000135046 Annexin A1
SAT1 Down ENSG00000130066 Spermidine/spermine N1-acetyltransferase 1
CNDP2 Down ENSG00000133313 Carnosine dipeptidase 2
PBX1 Down ENSG00000185630 PBX homeobox 1
aHuman Genome Organisation (HUGO) Gene Nomenclature Committee.
bCompared to the most aggressive cancers.
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The ML-generated segmentation masks, retrospectively
reviewed by an expert radiologist, were judged to include tissue
that was likely to represent the primary uterine tumor in as much
as 99.7% of the cases (all, except one/336 patients), pinpointing
the robustness of our ML-based segmentation method to segment
primary tumor tissue in EC.
However, in 29% (96/336) of the patients, the automated ML
algorithm yielded more than one segmentation mask, which
seemed partly to be caused by heterogeneous tumor growth and
partly represent non-tumor tissue in the uterus. In our radiomic
analyses we did not exclude any extrauterine segments, but rather
included all ML segments unfiltered, aiming to assess whether
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machine learning-based radiomic signatures were reproduced
without any human interventions or adjustments of segmentation
masks. Interestingly, this study demonstrates that the developed
ML-segmentation algorithm, despite involving segmented areas
outside the uterus, is able to capture and reproduce the radiomic
features and clusters of clinical relevance in EC.
The 11-gene signature we generated from the radiomic clusters
was strongly prognostic and validated in the full L1000 dataset and
in orthologous Agilent mRNA expression microarray and external
RNA sequencing data from TCGA. Two heat shock proteins
(HSPs), HSPA5 and HSP90AA1, were among the three upregu-
lated genes in the signature describing the most aggressive tumors.
Increased expression of HSPA5 and HSP90AA1 is in line with
previous observations by IHC in EC patients29,30. These HSPs can
activate the phosphoinositide 3-kinase/protein kinase B (PI3K/
AKT)-signaling pathway, the most frequently altered pathway in
EC31 likely by complexing with PI3K, as experimentally deter-
mined cell- and mouse models32,33. Interestingly, secreted
HSP90α has been shown to induce epithelial-to-mesenchymal
transition (EMT) in prostate- cells and tumors34, a process that is
also activated in aggressive and metastatic endometrial cancer35.
The third upregulated gene in the signature was the transcrip-
tional factor GATA3, a pioneer transcription factor yet to be
functionally described in EC, but that has been linked to the
regulation of estrogen signaling in breast cancer36. Eight
genes in the signature had reduced expression in the aggressive
cancers, and decreased expression of SCGB2A1 is known to be
associated with poor survival in EC37,38. The remaining genes are
less characterized in EC tumors but have interesting roles in
other cancers related to transcriptional regulation (PBX1 interacts
with the estrogen-axis in breast cancer39 and SAT1 functions as a
transcriptional regulator in aggressive brain tumors40), and
key signaling pathways including the transforming growth
factor β (TGFβ) pathway (GDF1541), the PI3K/AKT-pathway
(ANX1A42), and the Mitogen-activated protein kinase (MAPK)
pathway (CNDP243). However, for MMP7, involved in pro-
liferation and metastasis, most studies report elevated expression,
suggesting a possible adverse effect of this gene depending on the
type of cancer44. While the 11-gene signature was driven by dif-
ferentially expressed genes emerging from clusters 1 and cluster
2b, no genes reached significance when comparing clusters 2a and
−2b directly. It is possible that other mechanisms not investigated
in this study, such as DNA methylation45, could be associated with
the radiomic differences between clusters.
The gene signature correlated with the protein expression level
of the hormone receptors (ERα, PR, and AR), well known as
Fig. 3 The 11-gene signature score derived from radiomic clusters captures molecular and clinico-pathological patient characteristics and validates in
multiple datasets. a Top; Ranked 11-gene signature scores calculated on the L1000 gene expression dataset of overlapping patients with manual
segmentation-cohort -cohort radiomic data (L1000 start set; n= 51 patients). Middle; Clinico-pathological variables and biomarkers panel of protein levels
of hormone receptors measured by immunohistochemistry (IHC). Bottom: tentative molecular TCGA class as defined by the ProMisE classifier. Data for
the same patient is displayed vertically across panels. b–e Disease-specific Kaplan–Meier survival analysis of the 11-gene signature in the L1000 start set
(b n= 51 patients), Full L1000 dataset (c n= 392), L1000 low-risk cases (d evaluated by curettage/pipelle indicating endometrioid tumor grade 1 or grade
2, n= 296), and Agilent expression dataset (e n= 256). Note b and e are subsets of dataset c. The number of events in brackets. Mean signature value
was used as a cutoff for high or low signature score expression. Hashtag in TCGA pseudo classification (a); information extrapolated as non-MSI based on
negative POLE, normal p53 staining, and three negative MMRD markers (the fourth marker was not assessed). Asterisk: patient deemed as p53 abnormal
despite POLE mutated. Histological types; EEC endometrioid, CS carcinosarcoma, S serous, CC clear cell.
Table 3 Clinico-pathological variables in relation to the 11-gene signature score in the L1000 dataset (n= 392).
Variable Description Signature score, n (%) p valuea
Low (n= 245) High (n= 147)
Age <66 143 (70.1) 61 (29.9) 0.002
≥66 102 (54.3) 86 (45.7)
Histologic type Endometrioid 238 (75.6) 77 (24.4) <0.001
Non-endometrioid 7 (9.1) 70 (90.9)
Histologic gradeb Grade 1–2 212 (83.5) 42 (16.5) <0.001
Grade 3 23 (39.7) 35 (60.3)
FIGO stage I–II 223 (65.6) 117 (34.4) 0.002
III–IV 22 (42.3) 30 (57.7)
Myometrial infiltration <50% 165 (71.1) 67 (28.9) <0.001
≥50% 80 (50.0) 80 (50.0)
Lymph node metastasis No 179 (62.2) 109 (37.8) 0.006
Yes 13 (37.1) 22 (62.9)
Ploidy Diploid 148 (69.2) 66 (30.8) <0.001
Aneuploidy 20 (30.3) 46 (69.7)
ER protein expressionc High expression 184 (74.5) 63 (25.5) <0.001
Low expression 29 (30.2) 67 (69.8)
PR protein expressionc Positive 199 (77.4) 58 (22.6) <0.001
Negative 17 (19.3) 71 (80.7)
AR protein expressionc Positive 150 (73.9) 53 (26.1) <0.001
Negative 50 (43.9) 64 (56.1)
Missing data (numbers): Histologic grade (3).
Not assessed (numbers): Lymph node metastasis (69), Ploidy (112), ER (49), PR (47), and AR (75).
aCalculated with Chi-Square test or Fischer’s exact test, as appropriate.
bEndometrioid type only.
cProtein levels by immunohistochemistry (IHC).
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robust biomarkers in EC35,46,47. This finding was consistent
across all datasets investigated and emphasizes that the radiomic
profiles derived from radiologic image features can capture rele-
vant and well-described biology of the tumors. Interestingly, the
distribution of patients is also in accordance with the TCGA
classification31,48, with POLE positive tumors assigned to the low-
risk gene expression signature score, and p53 abnormal tumors
mainly found in the high-risk cluster. In a recent publication, a
classifier based on contrast-enhanced computed tomography
(CE-CT) for the identification of MSI and tumor mutation
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Fig. 4 Radiomic clustering of ML segmented tumors in 336 EC patients reproduces three distinct clusters with different prevalence of high-risk
features. a Preoperative pelvic MRI with automated ML-based tumor segmentation of EC tumor (red arrows) of a patient with endometrioid type, histologic
grade 2, and FIGO stage IIIC1. Tumor segmentation was performed by a machine learning (ML) algorithm trained on the segmentation data from the manual
segmentation cohort. The radiologic images of the ML-cohort of VIBE+C, ADC, b1000, and tumor segmentation were used for radiomic profiling similar to the
manual segmentation-cohort. b Heatmap depicting the three distinct radiomic clusters and corresponding clinico-pathologic features capturing different levels
of tumor aggressiveness. Patients in cluster 2a (n= 84) and 2b (n= 64) more often had clinico-pathological variables known to be associated with high-risk
disease, compared with that of patients in cluster 1 (n= 188). c–e Survival analysis in relation to the radiomic clusters highlighting a significantly poorer survival
for patients in cluster 2. Disease-specific survival comparing clusters 1 and 2a/b combined (c), all three clusters (d), or by recurrence (e). Number of events in
brackets. Histological types; EEC endometrioid, CS carcinosarcoma, S serous, CC clear cell, U undifferentiated.
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burden-high (TMB-H) cases was proposed based on a small
cohort of endometrial cancers14. In this classifier, peritumoral-
rim radiomic features were found to be highly important, sug-
gesting that tumors with high mutational burdens have a deli-
neation that can be captured by radiomic profiling14. However,
the poor soft-tissue resolution at CT often makes valid tumor
segmentations difficult, and MRI, yielding much better soft-tissue
resolution with an accurate depiction of tumor boundaries, is thus
likely to be better suited for whole-volume radiomic profiling.
Future radiogenomics studies should evaluate the feasibility of
determining the spectrum of TCGA molecular subtypes directly
from radiomic data using different imaging modalities in a large
cohort.
In the current study, we have demonstrated the translational
potential of integrating radiomic profiling with transcriptomic
profiling for better preoperative risk assessments in EC patients.
While our study has some limitations mainly linked to the ret-
rospective study design with some overlap of cases in the
expression datasets, we applied different and independent assays
for transcriptome profiling. MRIs were performed using both
1.5 T and 3 T scanners, with possible impact on the radiomic
profiles due to systematic differences in signal intensities, and we
applied separate Z-transformations for each dataset of the same
field strength to account for this. Despite these limitations, we
firstly describe distinct radiomic clusters comprising patient
groups with differential risk profiles. Secondly, we link these
radiomic clusters to differential gene expression and present a
gene signature score based on these genes that predicts aggressive
features and poor outcome. Thirdly, we demonstrate the feasi-
bility of automated ML-based tumor segmentations for expedited
radiomic profiling and clinical phenotyping in EC. Prospective
validation in larger and independent patient cohorts should
inform potential implementation in the clinic to enable better
prognostication and tailoring of treatment in EC.
Methods
Patient cohort and biospecimen collection. The current study was conducted
under Institutional Review Board (IRB)-approved protocols (2015/2333, 2015/548)
and biobank approval (2014/1907) with written informed consent from all patients.
Patients were diagnosed and treated at the same University Hospital (Haukeland
University Hospital, Bergen, Norway), which is a European Society for Gynecologic
Oncology (ESGO) accredited cancer center serving a population of ~1 million
inhabitants. Patients diagnosed with histologically confirmed EC during April
2009–July 2019 who had contrast-enhanced MRI performed preoperatively were
included and divided into training and a validation cohort as described below. Two
radiologists, each with more than 5 years of relevant clinical experience reported on
imaging variables and segmented the primary tumors. Clinical data were collected
retrospectively from medical records. Expert pathologists evaluated the resected
tumors, and tumor cellularity was quantified from hematoxylin- and eosin-stained
sections. Preoperative endometrial biopsies by curettage or pipelle were classified as
“low risk” from preoperative pathology finding consistent with endometrioid grade
1 or 2 tumors. Biopsies were included if tumor content was more than 70%. RNA
was extracted from fresh frozen tissues using Qiagen RNA easy kit (Hilden, Ger-
many) according to the manufacturer’s instructions.
Imaging protocol and preprocessing steps. Preoperative MRI was performed on
a 1.5 T Siemens Avanto running Syngo MR B17 (Erlangen, Germany) (n= 266)
using a six-channel body coil or on a 3 T Siemens Skyra running Syngo MR E11
(Erlangen, Germany) (n= 221) using an 18-channel-body-phased-array and a
spine-coil (Supplementary Table S7). Prior to imaging, 20 mg butylscopolamine
bromide (Buscopan, Boehringer Ingelheim, Germany) was administered intrave-
nously to reduce bowel peristalsis. A contrast-enhanced T1-weighted axial oblique
3D volumetric interpolated breath-hold (VIBE+ C) gradient-echo sequence with
fat saturation was acquired 2 min after injection of intravenous contrast agent
(0.1 mmol gadolinium/kg body weight, Dotarem, Guerbet, France). In addition, a
axial oblique diffusion-weighted imaging (DWI) sequence with b-values of 0 and
1000 s/mm2 (1.5 T) or 0, 500 s/mm2, and 1000 s/mm2 (3 T) was acquired (Sup-
plementary Table S7) in addition to standard T2-weighted sequences. All imaging
data were read and reported as part of the standard routine clinical workup prior to
treatment. DICOM images from T1 VIBE+ C and DWI were exported to NIFTI-1
format49 using the conversion tool “mri_convert” as part of “FreeSurfer”50.
Apparent diffusion coefficient maps (ADC) and b1000 images (DWI image for
b= 1000) derived from the DWI data were aligned with the T1-weighted contrast-
enhanced VIBE+ C sequence using ‘FLIRT’ from the FSL package51, leaving a total
of three image channels for further analysis.
Training- and validation imaging cohorts. In total, MRI examinations were
available for n= 487 patients diagnosed during April 2009 to July 2019; all
having visible primary tumors confirmed by a radiologist. The MRI data were
divided into a training set with manual tumor segmentations (manual seg-
mentation-cohort, n= 138) and a validation set with machine learning derived
tumor segmentations (ML-segmentation-cohort, n= 349). There were no sig-
nificant differences between patients in the two cohorts in terms of survival
(p= 0.8, Supplementary Fig. S3), or clinical variables (Supplementary Table S8)
except higher recurrence rate in the manually segmented dataset (p= 0.015),
which is likely due to longer follow-up time in a manually segmented cohort
(47.7 compared to 39.2 months in ML-cohort).
Two radiologists having experience with pelvic MRI outlined all primary
tumors in 3D on preoperative MRI in the manual segmentation-cohort (1.5 T,
n= 71; 3 T, n= 67). Tumor labeling was conducted on the VIBE+ C 2 min
post-contrast images on axial oblique (perpendicular to the long axis of the
uterus) slices, the boundaries of the primary tumor were manually drawn and
filled to become a binary mask. The remaining MRI examinations in the ML
cohort (1.5 T, n= 195; 3 T, n= 154) were used as a validation cohort with
machine learning-based automatic tumor segmentation comprising the ML
dataset. The automatic tumor segmentation was performed using a previously
published 3D UNet architecture available at Github. (https://github.com/ellisdg/
3DUnetCNN)52. We implemented a python wrapper for this library, facilitating
training and prediction of new datasets. All hyperparameters used in the training
process are in detail outlined in Hodneland et al.26. The same model was used for
the current task of segmenting tumors in the ML dataset. Model weights of the
trained network along with a python script (predictUNet3D.py) for predicting
primary tumor in new and unseen VIBE+ contrast 2 min datasets can be
downloaded from https://github.com/ehodneland/RadioGenomicsEC. The same
repository also contains code for the training of the network, as well as for
extraction and clustering of radiomic features. Finally, all patients (n= 487)
were assigned an MRI tumor mask segmentation, either by a radiologist or by
automatic segmentation.
Extraction of radiomic profiles. Radiomic features were automatically extracted
for the three abovementioned image channels from within the tumor masks, giving
a complete set of 53 radiomics features (Supplementary Table S9). For each patient,
one scalar value was reported per radiomic feature. The number of radiomic fea-
tures was selected lower than the number of patients to improve the performance
of the prediction model. Tumor volume “vol” was computed as the sum of voxels
within the tumor mask times the voxel volume.
To explore the extent of surface folding and irregular tumor shape decoupled
from tumor size itself, we initially considered tumor surface area and tumor surface
area/tumor volume. However, since both these parameters are inherently closely
linked to tumor volume, we created the parameter “normsurfvolratio”= (V/r3)/
(A/r2). In this formula, r is the radius of an imaginary sphere having the same
volume V as the tumor. The tumor volume V and the tumor area A were
normalized with r3 and r2, respectively, in order to remove direct dependencies on
tumor volume.
The features “clustersize” and “cluster index” arise from a k-means two-group
clustering of the image intensities within the tumor. Objects smaller than three
voxels were considered noise after clustering and therefore excluded, while the
average volume of the remaining objects were measured to become the
“clustersize”. The cluster index “clustindex” is the total number of spatially
disconnected objects within the two clusters. “Clustersize” and “clustindex” capture
random disorder within the tumor. The features “meaning” and “stdint” are mean
and the standard deviation within the tumor, respectively. The feature
“mean15perc” is the average intensity of the 15% lowest intensity voxels within the
tumor. Kurtosis, skewness, and entropy were calculated using “scipy.stats”53. A set
of Gabor filters was constructed using the function “gabor_kernel” from
“skimage.filters” leading to a 16-dimensional filter bank54. The filters were
convolved with the tumor image using ‘convolve’ from “scipy.ndimage”. The
convolved output was normalized by dividing with the tumor image itself, and the
summed output was divided by the number of filters. The final Gabor filter value
was reported as the variance of the filter outputs.
The 4D GLCM output matrix was averaged over the search angles and offsets,
and normalized to a sum of 1, becoming the GLCM matrix P. The element Pij
refers to how often a pixel with grayscale intensity value i is adjacent to a pixel with
intensity value j, applied to the given search angles and offsets. The GLCM
variables contrast, homogeneity, energy, and correlation were estimated by the
function “graycoprops” applying the formulas in Supplementary Table S9. The gray
level run length matrix (GLRLM) was computed using a tailored algorithm55. An
output matrix summing the filter response of all filtered angles were summed and
divided by the number of filters. The GLRLM matrix P was then normalized to a
sum of 1. The element Pij is the number of homogeneous runs of j voxels with
intensity i within the mask. The GLRLM variables short-run emphasis (SRE), long-
run emphasis (LRE), low gray level run emphasis (LGLRE), and high gray level run
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emphasis (HGLRE) were computed as in Supplementary Table S9. All GLCM and
GLRLM matrices were computed 2D-wise on paraxial images and later averaged
over all tumor slices prior to statistical analysis. Finally, each radiomic feature was
Z-transformed (i.e., scaling to standard deviation= 1 and translation to zero mean)
across the patients within the training cohort. To avoid selection bias in the
clustering analysis due to differences in image intensity between the magnetic field
strengths, a Z-transform was carried out separately for images from the 1.5 T and
3 T scanners.
Unsupervised clustering of radiomic features in the training cohort. Unsu-
pervised clustering was applied to all extracted features to group patients into
clusters of similar radiomic patterns. Initially, tumors manually segmented gen-
erated two groups using unsupervised k-means clustering with a squared Euclidean
distance measure applied to the image feature matrix56. Patients in the two clusters
displayed differences in clinical characteristics predicting clinical phenotype and
survival. With the aim to further refine variability in clinical phenotypes present in
the high-risk group, we subsequently performed another unsupervised k-means
clustering of the cluster exhibiting the most aggressive clinical characteristics
leading to two subclusters. This resulted in three distinct clusters, referred to as
cluster 1, cluster 2a, and cluster 2b. K-means clustering with random seed selection
is hampered by a non-convex optimization problem and may lead to different
results upon each execution cycle. Hence, for the sake of reproducibility, we pro-
ceeded with k-means clustering-subclustering (2+ 1) instead of k-means (K= 3).
The potentially more stable K-medoids algorithm for clustering was also explored
and yielded very similar results to that of K-means with similar risk profiles for the
three clusters.
We explored the robustness of the segmentations in terms of minor
segmentation errors by dilating and eroding the segmentation mask with a
3 × 3 × 3 structural elements of six connectivity on the training dataset. The
radiomic features were extracted and used for a k-means clustering into three
clusters as described.
Assignment of patients to clusters in the ML-cohort. In the ML cohort,
patients with no detectable tumor on MRI based on the machine learning
algorithm were excluded from further analysis of radiomic profiling (13/349). In
the remaining 336 patients, based on automatically segmented tumor volumes,
the texture features were Z-transformed for normalization. The normalization
parameters of scaling and translation derived from the manual segmentation
cohort were applied separately for the 1.5 T and 3 T data. In the next step, we
assigned previously unseen patients in the ML cohort to the clusters initially
generated from the training cohort. The Euclidean distance between the radio-
mic feature vector and the cluster centroids was computed for each patient in the
ML cohort, and each patient was assigned to belong to the closest cluster in
terms of computed distance. Image data from each patient was examined by
either one of two trained radiologists evaluating the accuracy of the ML-derived
segmentation masks. Out of 336 patients, they found one patient where the ML-
suggested lesion was not positioned inside the uterus, and therefore likely not
representative of a primary tumor. The automated segmentation algorithm
suggested more than one lesion in 29% (96/336) patients; all of them had one
lesion in the uterus likely to represent primary tumor, and the additional lesions
were in most cases located in putative non-malignant tissue in the uterus or in a
few cases located in outside the uterus. All masks were included in the further
radiomic profiling since the ML-based tumor segmentation was intentionally
conducted completely unsupervised without requiring any manual steps by
radiologists. The ranking of feature importance for discriminating clusters was
based on pairwise inter-distance cluster centroid distances comparing cluster 1
with −2a, cluster 1 with −2b, and cluster 2a with −2b.
Gene expression profiling. mRNA expression profiles were generated by the
L1000 approach57 for 392 patients. The L1000 expression data were generated
following an algorithm that extrapolates the expression of 978 directly measured
(landmark) genes via a method involving ligation-mediated amplification and
fluorescent labeling to obtain a transcriptional profile of 12328 genes in the full
L1000 dataset57. Replicate-collapsed z-scores (level-5 data) were used for sub-
sequent L1000 analysis. L1000 data was available for 51 patients in the MRI-
training set, and 112 patients in the validation set. In addition, orthologous mRNA
expression profiles were available from previous studies using Agilent microarrays
(n= 256), including data from overlapping patients (n= 98). In brief, Agilent
expression data were quantile normalized and log2 transformed from the Agilent
Whole Human Genome Microarray kit, 44k (Cat.no. G4112F), as previously
described35. Validation through TCGA mRNA exon sequencing expression data
(IlluminaHiSeq_RNASeqV2, log2 [RPKM+ 1] normalized), was performed on
data queried from the GDC portal https://www.portal.gdc.cancer.gov.
Differentially expressed genes and the 11-gene signature score. Analysis of
differentially expressed genes between radiomic clusters was performed with the
siggenes package in R (version 4.0.0). Significance analysis (SAM) was performed
based on selected Delta-values and false discovery rates (FDR), on clusters obtained
from unsupervised clustering of radiomic feature extracted matrices. The 11-gene
signature was constructed based on the most significant and overlapping genes in
SAM analysis employing either two clusters (cluster 1 vs. cluster 2b), or all three
clusters (Table 2; Supplementary Data 1). No genes reached significance comparing
clusters 2a and −2b in the 51-patient L1000 start set. The signature score of the
resulting 11 genes was calculated as the sum of upregulated genes minus the sum of
downregulated genes from z-normalized individual expression values35.
Molecular biomarkers and molecular classification. We determined biomarker
(protein) expression of hormone receptors (Estrogen Receptor Alpha [ERα], Pro-
gesterone Receptor [PR], Androgen Receptor [AR]) by immunohistochemical
(IHC) on tissue microarray slides, as previously described in refs. 35,46,47. Missing
hormone receptor status were extrapolated from expression data compared to cases
with both IHC evaluation and L1000 data available, using a mean expression for
high/positive or loss/negative markers, for the display of panel in Fig. 3 (n= 51
cases). We determined the TCGA molecular-like classes by following the algorithm
of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE;48).
This procedure represents a more clinically feasible classifier than the original
proposed by the TCGA31. The steps in ProMisE are to be applied sequentially.
First, the mismatch repair deficiency was determined (MMRD class; loss of either
of MSH6, PMS2, MLH1 or MSH2 by IHC;58). Second, the exonuclease domain of
polymerase-ε was sequenced (Sanger sequencing of POLE exons 9/11/13/14; POLE
class59;). Third, the status of protein 53 expression was determined (abnormal p53
by IHC [p53 abnormal, representing TP53 mutations]) or the alternative p53 wt
(p53 normal expression [p53 normal]). The resulting ProMisE classification then
provides substitution of the molecular classes originally defined as POLE-ultra-
mutators, MSI-hypermutators, copy-number(variant)-low (Endometrioid), and
copy-number-high (Serous-like) classes31. We identified four cases with POLE
mutations at p.P286R (n= 2), p.D287E (n= 1), and p.S297F (n= 1), all within
exon 9 in the manually segmented dataset with overlapping L1000 expression data
(n= 51).
Statistics. Data were analyzed using SPSS version 25 (SPSS INC., Chicago, IL) or R
(4.0.0). The level of statistical significance was set as p < 0.05. All reported p values
were unadjusted and two-sided. Associations between groups were evaluated using
the chi-square test for categorical variables or Fisher’s exact test as appropriate.
Kaplan–Meier curves and log-rank tests (Mantel–Cox) were applied for comparing
disease-specific and recurrence-free survival between clusters or signatures. The
date of primary surgery was defined as the entry date, and the date of death
specifically due to endometrial cancer was defined as an event for estimation of
disease-specific survival. Recurrence was defined as local recurrence/progression or
metastases at later time points.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Validation data are available from the TCGA database via https://
www.portal.gdc.cancer.gov and https://www.cbioportal.org60,61. The transcriptome
datasets are deposited at ArrayExpress with accession reference E-MTAB-501762 for
Agilent microarray data and E-MTAB-1066863 for L1000 data, respectively. Other data
of this study are available within supplementary files or the corresponding author upon
reasonable request and if in compliance with the general data protection regulation
(GDPR) and patient consents.
Code availability
Matlab and python codes for data processing and analysis, and example input data, are
available in the Github repository: https://github.com/ehodneland/RadioGenomicsEC
and archived in Zenodo https://doi.org/10.5281/zenodo.5617896.
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